FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
FDA General

FDA WEBVIEW CLOSED JULY 4TH WEEK

In annual observance of the Fourth of July (Independence Day) holiday in the U.S., FDA Webview closes its news operations until Monday, July 7.

latest-news-card-1
Medical Devices

Atmo Bios Gut Capsule Cleared by FDA

FDA clears an Atmo Biosciences 510(k) for the ingestible Atmo Gas Capsule System for assessing both whole and regional gut transit times.

latest-news-card-1
Human Drugs

Report Highlights Study Demographic Representation

A new FDA report examines the demographic representation of clinical trials supporting the approval of 50 novel drug therapies last year.

latest-news-card-1
Human Drugs

REMS Requirements Ended for CAR T Cell Therapies

FDA removes risk evaluation and mitigation strategies requirements for all currently approved CAR T cell therapies, saying the programs have burdened ...

latest-news-card-1
Human Drugs

UCB Positive Data for Epileptic Encephalopathy Drug

UCB reports positive data from a Phase 3 clinical trial evaluating fenfluramine as an adjunctive treatment for rare epileptic encephalopathy condition...

latest-news-card-1
Human Drugs

Appeals Court Backs FDAs Sameness Interpretation

An appeals court rules for FDA that a clinically superior drug is not the same as a drug that is otherwise the same.

latest-news-card-1
Human Drugs

NDA Filed for Nicotine Dependence Drug

Achieve Life Sciences files an NDA for cytisinicline for treating nicotine dependence as part of smoking cessation in adults.

latest-news-card-1
Human Drugs

Livmarli, Bylvay Get Liver Injury/Bleeding Updates

FDA issues safety-related labeling updates for two bile acid transport inhibitors Mirum Pharmaceuticals Livmarli and Ipsen Biopharmaceuticals Bylvay ...

Human Drugs

Antibacterial Therapies Development Q&A Guidance

FDA publishes a question-and-answer guidance to help sponsors develop new antibacterial drugs.

latest-news-card-1
Human Drugs

Altimmune Mixed Results for Pemvidutide in MASH

Altimmune reports mixed topline results today from its Phase 2b IMPACT trial evaluating pemvidutide in patients with metabolic dysfunction-associated ...